Moleculin Sets 1-for-20 Reverse Split Effective October 20
MBRX has more than doubled off its 52-week low of $0.161 on light trading volume (0.3× avg).
Summary
Moleculin will execute a 1-for-20 reverse split at 12:01 am ET on October 20, cutting shares outstanding from about 20.9 million to roughly 1.05 million while keeping authorized shares at 500 million. The move follows the September 18 8-K disclosing Nasdaq's Staff Determination Letter for failing the minimum bid price rule, and the August 24 proxy that sought shareholder approval for the split to regain compliance. This is the mechanical step to cure the listing deficiency, not a change in the underlying business. The company still carries going-concern doubt and has no committed financing for its Annamycin Phase 2/3 MIRACLE trial, so the split buys listing time but does not address the cash shortfall. Watch whether MBRX holds above $1 post-split and whether Nasdaq confirms compliance; any further equity raise at these levels would be highly dilutive.
At the time of this announcement, MBRX was trading at $0.36 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.5M. The 52-week trading range was $0.16 to $15.75. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.